Surrozen grabs $33M, joins startups looking to spark a comeback in regenerative med
In another sign that the long, cold winter for regenerative medicine may be coming to an end, The Column Group led a $33 million startup round for Surrozen, a new Bay Area biotech coming out of the labs at Stanford.
The key figure in this startup is Christopher Garcia, a Stanford investigator who’s been drawn into the world of Wnt. While much of his labor has centered on cancer research, he’s also spent time developing Wnt surrogates that can play the same role as the natural proteins in forming tissue and spurring repair, but hopefully with better drug-like properties that will make them simpler to manufacture and test in humans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
